Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus PROMPT PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus PROMPT PHENYTOIN SODIUM.
PARADIONE vs PROMPT PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
100 mg orally three times daily; maximum 600 mg/day.
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant